Description:FIELD OF THE INVENTION
The present invention relates to the field of biomaterials and tissue engineering for wound management. More specifically, it concerns the design and fabrication of a bioengineered scaffold system intended for treating wounds affected by myiasis. The invention integrates antimicrobial and regenerative functionalities within a single scaffold platform to accelerate healing, prevent reinfestation, and restore tissue integrity.
BACKGROUND OF THE INVENTION
Myiasis is a parasite infection that happens when fly larvae get into open wounds. It is a big problem for doctors, especially in tropical and subtropical areas. These wounds often have a lot of tissue death, bacterial infection, swelling, and slow healing. Because of the complicated tissue damage and high risk of infection, traditional ways of taking care of wounds don't always work well for myiasis. There is a pressing need for an effective, bioactive wound management strategy that can support tissue regeneration, prevent secondary infection, and accelerate healing. Developing a biocompatible scaffold design tailored for myiasis-affected wounds could provide a structured platform for wound healing by facilitating cell proliferation, providing antimicrobial action, and enabling the gradual restoration of damaged tissue.
US20230340114A1: The present disclosure provides anti-LILRB4 antibodies or antigen-binding fragments thereof, anti-LILRB4 chimeric antigen receptor protein, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
US10022425B2: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing.
There is no one treatment that can heal wounds that have been infected with myiasis. They can get rid of dead tissue and treat infections, but they don't do a great job of stopping reinfestation or helping tissue grow again. Localized, controlled drug distribution and structural support make it harder for healing to happen. This highlights how crucial it is to develop a strategy to treat wounds that incorporates a scaffold that can accomplish more than one function.
SUMMARY OF THE INVENTION
This summary is provided to introduce a selection of concepts, in a simplified format, that are further described in the detailed description of the invention.
This summary is neither intended to identify key or essential inventive concepts of the invention and nor is it intended for determining the scope of the invention.
Myiasis is a parasitic condition caused by the infestation of human or animal tissue by fly larvae. The larvae feed on necrotic or living tissue, leading to significant tissue destruction, secondary infections, inflammation, and delayed wound healing. The condition is especially prevalent in tropical and subtropical regions, where poor hygiene, chronic wounds, and open sores increase vulnerability to larval invasion.
Traditional management of myiasis involves mechanical removal of larvae, administration of antiparasitic drugs like ivermectin, use of antibiotics such as metronidazole, and application of wound dressings to control infection and promote healing. However, these treatments often provide only temporary relief and fail to simultaneously address the structural and biological requirements for tissue regeneration.
Wound dressings such as hydrogels, alginate, honey-based, or silver-impregnated materials offer some antimicrobial protection but do not prevent reinfestation or support full restoration of damaged tissue. Biological debridement using sterile larvae (as in BioBag or LarvE) assists in removing necrotic tissue but does not actively induce cellular regeneration. As a result, healing remains incomplete and recurrence is common in high-risk patients.
The lack of an integrated solution that combines antimicrobial protection, larval control, and regenerative capability highlights a major therapeutic gap. An effective treatment for myiasis-affected wounds must not only eliminate pathogens and parasites but also provide a structural matrix that facilitates cell proliferation and tissue repair.
Scaffold-based wound healing systems have demonstrated potential for chronic wounds and burns. However, no commercially available scaffold has been optimized for the complex biological environment of myiasis. Therefore, a bioactive scaffold that delivers drugs locally, inhibits microbial growth, and promotes tissue regeneration would represent a significant advancement in myiasis treatment and wound care.
The current approach emphasizes the development of scaffold materials designed to effectively treat myiasis infections. This method is cost-effective, eco-friendly, and non-toxic, bio-active during the implantation.
To further clarify advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof, which is illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail with the accompanying drawings.
The present invention provides a bioengineered scaffold system specifically designed for the treatment of myiasis-affected wounds. The invention integrates regenerative, antimicrobial, and antiparasitic features into a single scaffold structure, offering a holistic therapeutic approach to wound management.
The scaffold comprises biocompatible and biodegradable materials that mimic the extracellular matrix, providing mechanical stability and biological support for tissue regeneration. The material composition is selected to be eco-friendly, non-toxic, and bio-active during implantation, ensuring safety and functionality within the wound site.
In one embodiment, the scaffold is designed to deliver antiparasitic and antibacterial agents in a controlled, sustained manner, maintaining therapeutic drug concentrations at the wound surface over time. This targeted release helps eliminate larvae, suppress bacterial colonization, and prevent reinfestation.
The structural design of the scaffold provides a porous, interconnected network to facilitate oxygen exchange, fluid transport, and cell migration, thereby enhancing granulation tissue formation and re-epithelialization. The scaffold acts as both a physical barrier and a regenerative platform.
The invention thus addresses two major challenges of myiasis treatment — infection management and tissue restoration — through a single, multifunctional biomaterial platform. The scaffold can also be adapted with natural or synthetic polymers to suit specific wound types or healing rates.
Overall, this invention introduces a transformative wound healing strategy capable of accelerating recovery, minimizing complications, and restoring skin architecture in myiasis-affected wounds.
BRIEF DESCRIPTION OF THE DRAWINGS
The illustrated embodiments of the subject matter will be understood by reference to the drawings, wherein like parts are designated by like numerals throughout. The following description is intended only by way of example, and simply illustrates certain selected embodiments of devices, systems, and methods that are consistent with the subject matter as claimed herein, wherein:
FIGURE 1: SYSTEM ARCHITECTURE
The figures depict embodiments of the present subject matter for the purposes of illustration only. A person skilled in the art will easily recognize from the following description that alternative embodiments of the structures and methods illustrated herein may be employed without departing from the principles of the disclosure described herein.
DETAILED DESCRIPTION OF THE INVENTION
The detailed description of various exemplary embodiments of the disclosure is described herein with reference to the accompanying drawings. It should be noted that the embodiments are described herein in such details as to clearly communicate the disclosure. However, the amount of details provided herein is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the scope of the present disclosure as defined by the appended claims.
It is also to be understood that various arrangements may be devised that, although not explicitly described or shown herein, embody the principles of the present disclosure. Moreover, all statements herein reciting principles, aspects, and embodiments of the present disclosure, as well as specific examples, are intended to encompass equivalents thereof.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments. As used herein, the singular forms “a",” “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises,” “comprising,” “includes” and/or “including,” when used herein, specify the presence of stated features, integers, steps, operations, elements and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components and/or groups thereof.
It should also be noted that in some alternative implementations, the functions/acts noted may occur out of the order noted in the figures. For example, two figures shown in succession may, in fact, be executed concurrently or may sometimes be executed in the reverse order, depending upon the functionality/acts involved.
In addition, the descriptions of "first", "second", “third”, and the like in the present invention are used for the purpose of description only, and are not to be construed as indicating or implying their relative importance or implicitly indicating the number of technical features indicated. Thus, features defining "first" and "second" may include at least one of the features, either explicitly or implicitly.
Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which example embodiments belong. It will be further understood that terms, e.g., those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
The current approach emphasizes the development of scaffold materials designed to effectively treat myiasis infections. This method is cost-effective, eco-friendly, and non-toxic, bio-active during the implantation
The interesting thing about this notion is that it entails producing bioengineered scaffolds that are developed particularly for wounds that have myiasis. These scaffolds will have things that kill bacteria and help tissue grow again. This will not only kill parasites, but it will also help wounds heal faster. This procedure is different from traditional therapies since it kills larvae and helps tissue heal at the same time. It does this by releasing drugs over time and using biocompatible materials, which get around the problems with current treatments for these kinds of complicated and infected wounds.
The invention concerns the fabrication and application of a bioactive scaffold structure tailored for myiasis-affected wounds. The scaffold is designed to act as both a therapeutic and regenerative interface, combining drug delivery, mechanical protection, and tissue engineering properties.
The base scaffold material may comprise biocompatible polymers such as chitosan, alginate, collagen, or a combination thereof, chosen for their biodegradability and wound-healing compatibility. These materials are processed to form a porous matrix that emulates the extracellular matrix (ECM), supporting cell adhesion, proliferation, and differentiation.
During fabrication, techniques such as electrospinning, freeze-drying, or solvent casting may be employed to achieve desired porosity and mechanical strength. The interconnected pores facilitate gaseous exchange, nutrient diffusion, and waste removal — critical parameters for proper wound healing in infected environments.
The scaffold is impregnated with antimicrobial and antiparasitic agents, such as metronidazole or ivermectin, for sustained local release. The encapsulated drugs diffuse slowly from the matrix, ensuring continuous therapeutic activity at the wound site without frequent dressing changes.
Upon application to a myiasis-affected wound, the scaffold forms a protective covering that prevents external contamination while maintaining a moist microenvironment favorable for healing. The local drug release eliminates larvae and pathogenic microorganisms residing in necrotic tissue.
Simultaneously, the scaffold’s bioactive surface interacts with fibroblasts, keratinocytes, and endothelial cells, stimulating granulation tissue formation and angiogenesis. The biomaterial degradation rate is synchronized with new tissue formation, ensuring gradual replacement of the scaffold by natural tissue.
The invention may incorporate natural extracts or metallic nanoparticles, such as silver or zinc oxide, to further enhance antimicrobial efficacy without compromising biocompatibility. These additives provide additional protection against bacterial resistance and reinfestation.
The structural and chemical composition of the scaffold ensures adequate mechanical strength while remaining flexible and conformable to irregular wound geometries. The design prevents larval penetration and supports a sterile healing environment.
During the healing process, the scaffold gradually degrades into non-toxic byproducts, which are naturally absorbed or excreted by the body. This biodegradation eliminates the need for secondary removal procedures.
The scaffold can be sterilized using gamma irradiation or ethylene oxide before application to maintain sterility and biocompatibility. Drug loading and release kinetics may be adjusted by modifying polymer concentration, pore size, or cross-linking density.
The scaffold acts as both a passive dressing and an active therapeutic system, combining the structural integrity of a wound dressing with the pharmacological activity of a drug delivery system. It bridges the gap between infection control and tissue engineering.
By integrating regenerative and antimicrobial features, the invention enables rapid recovery, reduces wound care frequency, and minimizes the risk of chronic infection or reinfestation.
The working methodology involves cleaning the wound site, applying the scaffold directly over the affected region, and securing it to ensure intimate contact. The scaffold’s surface rapidly conforms to wound contours, initiating simultaneous drug diffusion and cellular colonization.
Over the healing period, the scaffold releases drugs at controlled rates, kills residual larvae, and facilitates epithelial cell migration from wound edges toward the center. Eventually, the scaffold disintegrates, leaving behind newly regenerated, infection-free tissue.
The invention provides a cost-effective and eco-friendly alternative to conventional myiasis treatments. Its multifunctional design combines physical protection, chemical therapy, and biological regeneration, ensuring comprehensive healing outcomes.
Thus, the proposed scaffold design represents a novel, clinically adaptable solution for effective management of myiasis-affected wounds, addressing infection eradication, tissue recovery, and reinfestation prevention in a single step.
 
, Claims:1. A scaffold-based wound healing system for the treatment of myiasis-affected wounds comprising a biocompatible and biodegradable scaffold structure configured for facilitating tissue regeneration, preventing reinfestation, and enabling sustained localized drug delivery.
2. The system as claimed in claim 1, wherein the scaffold is fabricated from natural or synthetic biomaterials selected from chitosan, alginate, collagen, or combinations thereof.
3. The system as claimed in claim 1, wherein the scaffold possesses interconnected pores allowing gaseous exchange, nutrient diffusion, and cellular migration.
4. The system as claimed in claim 1, wherein the scaffold incorporates antimicrobial and antiparasitic agents for localized controlled release.
5. The system as claimed in claim 1, wherein the scaffold further includes bioactive additives such as metallic nanoparticles or natural extracts to enhance antimicrobial efficacy.
6. The system as claimed in claim 1, wherein the scaffold is designed for biodegradation in synchronization with tissue regeneration.
7. The system as claimed in claim 1, wherein the scaffold maintains flexibility and conformability to adapt to irregular wound geometries.
8. A method for treating myiasis-affected wounds comprising implanting the scaffold as claimed in claim 1 over an infected wound region, enabling localized release of therapeutic agents, and facilitating wound healing through tissue regeneration.
9. The method as claimed in claim 8, further comprising allowing gradual biodegradation of the scaffold while being replaced by regenerated tissue, thereby restoring structural and functional integrity of the wound site.
10. The method as claimed in claim 8, further comprising maintaining sustained antimicrobial activity at the wound surface to eliminate larvae and prevent reinfestation during the healing process.